Clinical Trials Browser

Head and Neck Neoplasms

NCT07015333 2025-06-11

Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab

Completed

31 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04359199 2023-02-10

QUASAR

Unknown

42 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT04672772 2022-03-23

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

Completed

531 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01466257 2017-05-19

Biomarkers in Patients With Head and Neck Cancer

Completed

70 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01466244 2017-05-17

Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397

Completed

42 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01075828 2014-08-29

Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea

Completed

221 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT01080066 2014-07-08

A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)

Completed

215 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma

NCT01075841 2014-07-02

A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck

Withdrawn

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms, Squamous Cell

Clinical Trials

Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer

Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab

QUASAR

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

Biomarkers in Patients With Head and Neck Cancer

Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397

Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea

A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)

A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck